Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide and imposing a significant social and economic burden. Despite extensive research, there is still no effective cure for this disease. AD is multifactorial and involves multiple etiopathogenic mechanisms...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexey Simakov, Stecy Chhor, Lhassane Ismaili, Hélène Martin
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/30/9/2048
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850279040379781120
author Alexey Simakov
Stecy Chhor
Lhassane Ismaili
Hélène Martin
author_facet Alexey Simakov
Stecy Chhor
Lhassane Ismaili
Hélène Martin
author_sort Alexey Simakov
collection DOAJ
description Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide and imposing a significant social and economic burden. Despite extensive research, there is still no effective cure for this disease. AD is multifactorial and involves multiple etiopathogenic mechanisms, one of which is oxidative stress. Consequently, the Nrf2/ARE pathway, which regulates the expression of cellular defense genes, including those for antioxidant enzymes, is considered to be a prospective therapeutic target for AD. Meanwhile, multitarget-directed ligands (MTDLs) are a promising approach for developing effective AD medications. In this regard, we evaluated the antioxidant potential of eight chromone-containing MTDLs in vitro, including Nrf2 transcriptional activation potencies, Nrf2/ARE downstream genes activation, and antioxidant effects in vitro. All tested compounds effectively activated the Nrf2/ARE pathway. Notably, compounds <b>4b</b>, <b>4c</b>, <b>4f</b>, and <b>4h</b> demonstrated the highest Nrf2 activation potencies, while compounds <b>4b</b>, <b>4c</b>, <b>4d</b>, and <b>4g</b> significantly induced the expression of Nrf2-target antioxidant genes, specifically NQO1 and HO1. Additionally, compound <b>4d</b> exhibited a significant antioxidant effect in vitro. These findings encourage further investigation of the studied compounds, with particular emphasis on compound <b>4d</b> as the most promising candidate.
format Article
id doaj-art-90fdb60d60ef4ebab510dd331a08b75e
institution OA Journals
issn 1420-3049
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj-art-90fdb60d60ef4ebab510dd331a08b75e2025-08-20T01:49:14ZengMDPI AGMolecules1420-30492025-05-01309204810.3390/molecules30092048Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease TreatmentAlexey Simakov0Stecy Chhor1Lhassane Ismaili2Hélène Martin3Université Marie et Louis Pasteur, INSERM UMR1322 LINC, F-25000 Besançon, FranceUniversité Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besançon, FranceUniversité Marie et Louis Pasteur, INSERM UMR1322 LINC, F-25000 Besançon, FranceUniversité Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besançon, FranceAlzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide and imposing a significant social and economic burden. Despite extensive research, there is still no effective cure for this disease. AD is multifactorial and involves multiple etiopathogenic mechanisms, one of which is oxidative stress. Consequently, the Nrf2/ARE pathway, which regulates the expression of cellular defense genes, including those for antioxidant enzymes, is considered to be a prospective therapeutic target for AD. Meanwhile, multitarget-directed ligands (MTDLs) are a promising approach for developing effective AD medications. In this regard, we evaluated the antioxidant potential of eight chromone-containing MTDLs in vitro, including Nrf2 transcriptional activation potencies, Nrf2/ARE downstream genes activation, and antioxidant effects in vitro. All tested compounds effectively activated the Nrf2/ARE pathway. Notably, compounds <b>4b</b>, <b>4c</b>, <b>4f</b>, and <b>4h</b> demonstrated the highest Nrf2 activation potencies, while compounds <b>4b</b>, <b>4c</b>, <b>4d</b>, and <b>4g</b> significantly induced the expression of Nrf2-target antioxidant genes, specifically NQO1 and HO1. Additionally, compound <b>4d</b> exhibited a significant antioxidant effect in vitro. These findings encourage further investigation of the studied compounds, with particular emphasis on compound <b>4d</b> as the most promising candidate.https://www.mdpi.com/1420-3049/30/9/2048antioxidant effectNrf2chromoneMTDLsAlzheimer’s disease
spellingShingle Alexey Simakov
Stecy Chhor
Lhassane Ismaili
Hélène Martin
Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
Molecules
antioxidant effect
Nrf2
chromone
MTDLs
Alzheimer’s disease
title Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
title_full Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
title_fullStr Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
title_full_unstemmed Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
title_short Nrf2 Activation and Antioxidant Properties of Chromone-Containing MTDLs for Alzheimer’s Disease Treatment
title_sort nrf2 activation and antioxidant properties of chromone containing mtdls for alzheimer s disease treatment
topic antioxidant effect
Nrf2
chromone
MTDLs
Alzheimer’s disease
url https://www.mdpi.com/1420-3049/30/9/2048
work_keys_str_mv AT alexeysimakov nrf2activationandantioxidantpropertiesofchromonecontainingmtdlsforalzheimersdiseasetreatment
AT stecychhor nrf2activationandantioxidantpropertiesofchromonecontainingmtdlsforalzheimersdiseasetreatment
AT lhassaneismaili nrf2activationandantioxidantpropertiesofchromonecontainingmtdlsforalzheimersdiseasetreatment
AT helenemartin nrf2activationandantioxidantpropertiesofchromonecontainingmtdlsforalzheimersdiseasetreatment